Ratios

		vs industry	vs history
P/B	2.87	ZIOP's P/B is ranked lower than 58% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 3.80 vs. ZIOP: 2.87 )	ZIOP' s 10-Year P/B Range Min: 2.5   Max: 8.4 Current: 2.87 2.5 8.4
P/S	166.67	ZIOP's P/S is ranked lower than 93% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 6.90 vs. ZIOP: 166.67 )	ZIOP' s 10-Year P/S Range Min: 0   Max: 622 Current: 166.67 0 622
EV-to-EBIT	-0.85	ZIOP's EV-to-EBIT is ranked higher than 70% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 14.61 vs. ZIOP: -0.85 )	ZIOP' s 10-Year EV-to-EBIT Range Min: 6.5   Max: 9.4 Current: -0.85 6.5 9.4

Valuation & Return

		vs industry	vs history
Price/Net Cash	3.6	ZIOP's Price/Net Cash is ranked higher than 83% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 8.80 vs. ZIOP: 3.6 )	ZIOP' s 10-Year Price/Net Cash Range Min: 4.3   Max: 8.5 Current: 3.6 4.3 8.5
Price/Net Current Asset Value	178	ZIOP's Price/Net Current Asset Value is ranked higher than 98% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 32.60 vs. ZIOP: 178 )	ZIOP' s 10-Year Price/Net Current Asset Value Range Min: 220.5   Max: 416 Current: 178 220.5 416
Price/Tangible Book	2.9	ZIOP's Price/Tangible Book is ranked higher than 79% of the 349 Companies in the Global Biotechnology industry. ( Industry Median: 4.70 vs. ZIOP: 2.9 )	ZIOP' s 10-Year Price/Tangible Book Range Min: 4.1   Max: 6.7 Current: 2.9 4.1 6.7

Business Description

ZIOPHARM Oncology, Inc. is a Delaware Corporation. It is a biopharmaceutical company engaged in the development and commercialization of small molecule and synthetic biology approaches to new cancer therapies. Palifosfamide (Zymafos or ZIO-201) is a novel DNA cross-linker that in preclinical study has been shown to bypass resistance mediated by aldehyde dehydrogenase (ALDH), in addition to conferring a favorable toxicity profile compared to other in-class agents. Palifosfamide, administered intravenously, is currently in a randomized, double-blinded, placebo-controlled Phase 3 trial for the treatment of metastatic soft tissue sarcoma in the front-line setting. The Company is also currently completing a Phase 1 study of palifosfamide in combination with standard of care for addressing small cell lung cancer; an investigational new drug application has been accepted for the oral form of palifosfamide. DNA-based therapeutics (synthetic biology), in partnership with Intrexon Corporation, include two clinical-stage product candidates, both of which are DNA IL-12 using the RheoSwitch Therapeutic System to be turned on/off by an oral activator ligand and are currently in Phase 1. Additionally, multiple INDs are expected in the next 12-24 months resulting from preclinical and discovery work underway to advance multiple antibody, immunotoxin, and protein decoy candidates, systemic delivery and a next generation RheoSwitch Therapeutic System. Indibulin (Zybulin or ZIO-301) is a novel, oral tubulin binding agent that is expected to have several potential benefits including oral dosing, application in multi-drug resistant tumors, no neuropathy and a quite tolerable toxicity profile. It is currently being studied in Phase 1/2 in metastatic breast cancer. Darinaparsin (Zinapar or ZIO-101) is a novel mitochondrial- and hedgehog-targeted agent (organic arsenic) currently in a solid tumor Phase 1 study with oral administration and has been developed intravenously for the treatment of relapsed peripheral T-cell lymphoma. ZIOPHARM's operations are located in Boston, MA, Germantown, MD and New York City.
Company Website
SEC Reports

Industry:	Biotechnology
Compare:	NVO, AMGN, GILD, BIIB, CELG
Traded in other countries:	WEK.Germany

» More Articles for ZIOP

Headlines

Articles On GuruFocus.com

Bass’ New Buy – ZIOPHARM Oncology Inc. May 16 2013

The Far-Off Four, 52-week Lows Held by Gurus May 11 2013

Personalized Checklist